LOH 100
Alternative Names: LOH-100Latest Information Update: 05 Feb 2025
At a glance
- Originator Lohocla Research
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Unspecified
Most Recent Events
- 05 Feb 2025 LOH 100 is available for licensing as of 20 Jan 2025. https://lohocla.com/research/partner/
- 20 Jan 2025 Preclinical trials in Unspecified in USA (unspecified route) (Lohocla Research pipeline, January 2025)